Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Description

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Conditions

Pancreas Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Condition
Pancreas Cancer
Intervention / Treatment

-

Contacts and Locations

Louisville

University of Louisville, Louisville, Kentucky, United States, 40202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * greater than or equal to 18 years of age
  • * diagnosed with stage III pancreatic cancer
  • * tumor is measurable
  • * GFR \> mL/min/1.73m2
  • * willing and able to comply with protocol requirements
  • * AST/ALT \>3 times upper limit of normal
  • * stable surgical post-operative course as defined by operative surgeon
  • * participating in another clinical trial for the treatment of cancer at the time of screening
  • * pregnant or currently breast feeding
  • * have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure
  • * have non-removable implants with metal parts within 1 cm of the target lesion
  • * had a myocardial infarction within 3 months prior to enrollment

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Louisville,

Robert Martin, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

2024-07-31